IP Library › Granted Patent US 9,370,538
Granted Patent B2
US 9,370,538 · App. 13/884,514 · Granted Jun 21, 2016

Non-replicating probiotic micro-organisms protect against upper respiratory tract infections

Inventors: Valerie Petit (Thonon-les-Bains, FR); Clara Lucia Garcia-Rodenas (Forel, CH); Monique Julita (Prilly, CH); Annick Mercenier (Bussigny, CH); Guenolee Prioult (Bern, CH); Sophie Nutten (Palezieux-Village, CH)
Assignee: Nestec S.A.
A61K35/741A61K35/742A61K35/745A61K35/747C12N1/20A61K35/74A61K38/00A61K39/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,370,538
App. No.
13/884,514
Granted
Jun 21, 2016
Kind
B2
Abstract

The present invention relates to non-replicating probiotic micro-organisms and their health benefits. For example, the present invention relates to compositions comprising non-replicating probiotic micro-organisms for use in the treatment of prevention of upper respiratory tract infections and/or their symptoms. Embodiments of the present invention provide means to help parents to protect their children from such upper respiratory tract infections.

Claims (16)

1. A method for treatment of rhinitis and/or its symptoms, the method comprising:

administering to an individual in need of same a composition comprising non-replicating probiotic micro-organisms that have been rendered non-replicating by a heat-treatment at 120-140° C. for about 1-120 seconds, the non-replicating probiotic micro-organisms selected from the group consisting of Bifidobacterium longum BB536 (ATCC BAA-999), Bifidobacterium longum NCC 2705 (CNCM I-2618), Bifidobacterium breve NCC 2950 (CNCM I-3865), Bifidobacterium lactis NCC 2818 (CNCM I-3446), Lactobacillus paracasei NCC 2461 (CNCM I-2116), Lactobacillus rhamnosus NCC 4007 (CGMCC 1.3724), Lactobacillus casei CTP31 (NCC 4006), Lactobacillus acidophilus NCC 3009 (ATCC 700396), Lactobacillus casei ACA-DC 6002 (NCC 1825), Escherichia coli Nissle (DSM 6601), Lactobacillus bulgaricus NCC15, Lactobacillus lactis NCC 2287, S. thermophilus NCC2019, and combinations thereof.

2. The method in accordance with claim 1 wherein the individual is a child.

3. The method in accordance with claim 1 wherein the heat treatment is performed at a temperature from 120-140° C. for 5-15 seconds.

4. The method in accordance with claim 1 wherein the individual is a child, and the composition strengthens the child's ability to fight upper respiratory tract infections.

5. The method in accordance with claim 1 comprising the step of reducing the time the rhinitis will last.

6. The method in accordance with claim 1 comprising the step of helping children to get upper respiratory tract infections less often.

7. The method in accordance with claim 1 wherein the composition comprises the non replicating probiotic micro-organisms in an amount corresponding to about 10 6 to 10 12 cfu.

8. The method in accordance with claim 1 wherein the heat-treatment is performed at 120° C. to 140° C. for 5-15 seconds.

9. A method for treatment of rhinitis and/or its symptoms, the method comprising:

administering to an individual in need of same a composition comprising non-replicating probiotic micro-organisms that have been rendered non-replicating by a heat treatment performed at a temperature from 120-140° C. for 5-15 seconds, and the non-replicating probiotic micro-organisms are selected from the group consisting of Lactobacillus paracasei NCC 2461, Lactobacillus rhamnosus NCC 4007, and combinations thereof.

10. A method for treatment of rhinitis and/or its symptoms, the method comprising:

administering to an individual in need of same a composition comprising non-replicating probiotic micro-organisms that have been rendered non-replicating by a heat-treatment at 120-140° C. for about 1-120 seconds, wherein the composition comprises probiotics, and at least 90% of the probiotics are the non-replicating probiotic micro-organisms.

11. The method in accordance with claim 1 wherein the composition contains about 0.005 mg-1000 mg non-replicating micro-organisms per daily dose.

12. The method in accordance with claim 1 wherein the individual has a symptom selected from the group consisting of cough, sore throat, runny nose, nasal congestion, headache, low grade fever, facial pressure, sneezing, and combinations thereof.

13. The method in accordance with claim 1 , wherein the probiotic micro-organisms are selected from the group consisting of Bifidobacterium longum BB536 (ATCC BAA-999), Lactobacillus casei CTP31 (NCC 4006), and a combination thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2013
From: PETIT, VALERIE; GARCIA-RODENAS, CLARA; JULITA, MONIQUE; MERCENIER, ANNICK; PRIOULT, GUENOLEE; NUTTEN, SOPHIE HELENE
To: NESTEC S.A.
Reel/Frame 030718/0123 →
Priority Claims (1)
EP 10190819 · Nov 11, 2010 · regional
Continuity (1)
Related Publication 20130224253A1 · Aug 29, 2013